Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

Paul Deep, Alain Dagher, Abbas Sadikot, Albert Gjedde, Paul Cumming

Research output: Contribution to journalArticle

Abstract

The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine increases the decarboxylation rate of 6-[18F]fluoro-L-DOPA (FDOPA), an exogenous substrate for DDC, in healthy human brain. Radioactivity concentrations in brain tissue of neurologically normal volunteers (n = 5) injected intravenously with FDOPA (~4.5 mCi) were recorded by positron emission tomography (PET) for 120 min, first in a baseline condition, and again following three consecutive days of treatment with amantadine (100 mg/day, p.o.). Data from four telencephalic regions of interest containing appreciable DDC activity were analyzed with the tissue slope-intercept plot, using cerebellar cortex as the reference tissue, to estimate a coefficient of in situ FDOPA decarboxylation (k3(r), min-1). Mean estimates of k3(r) were increased following amantadine treatment in caudate nucleus (+12%), putamen (+28%), ventral striatum (+27%), and frontal cortex (+9%). For an initial confidence level of 95%, paired one-sided Student's t-tests with Bonferroni correction for multiple comparisons revealed a statistically significant drug effect in ventral striatum. Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti-parkinsonian properties of amantadine. Nonetheless, PET studies in parkinsonian patients using higher, clinically effective doses of amantadine may reveal more pronounced enhancements of cerebral DDC activity.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalSynapse
Volume34
Issue number4
DOIs
StatePublished - Dec 15 1999
Externally publishedYes

Fingerprint

Dopa Decarboxylase
Amantadine
N-Methyl-D-Aspartate Receptors
Brain
Decarboxylation
Positron-Emission Tomography
Telencephalon
Cerebellar Cortex
Caudate Nucleus
Putamen
Glutamate Receptors
Frontal Lobe
Radioactivity
Parkinson Disease
Healthy Volunteers
Students
Therapeutics

Keywords

  • Caudate
  • Coefficient of decarboxylation
  • FDOPA
  • Fluorodopa
  • Parkinson's disease
  • PET
  • Putamen

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology
  • Pharmacology

Cite this

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. / Deep, Paul; Dagher, Alain; Sadikot, Abbas; Gjedde, Albert; Cumming, Paul.

In: Synapse, Vol. 34, No. 4, 15.12.1999, p. 313-318.

Research output: Contribution to journalArticle

Deep, Paul ; Dagher, Alain ; Sadikot, Abbas ; Gjedde, Albert ; Cumming, Paul. / Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. In: Synapse. 1999 ; Vol. 34, No. 4. pp. 313-318.
@article{1886573cc1f5483bb0f286b352591859,
title = "Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine",
abstract = "The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine increases the decarboxylation rate of 6-[18F]fluoro-L-DOPA (FDOPA), an exogenous substrate for DDC, in healthy human brain. Radioactivity concentrations in brain tissue of neurologically normal volunteers (n = 5) injected intravenously with FDOPA (~4.5 mCi) were recorded by positron emission tomography (PET) for 120 min, first in a baseline condition, and again following three consecutive days of treatment with amantadine (100 mg/day, p.o.). Data from four telencephalic regions of interest containing appreciable DDC activity were analyzed with the tissue slope-intercept plot, using cerebellar cortex as the reference tissue, to estimate a coefficient of in situ FDOPA decarboxylation (k3(r), min-1). Mean estimates of k3(r) were increased following amantadine treatment in caudate nucleus (+12{\%}), putamen (+28{\%}), ventral striatum (+27{\%}), and frontal cortex (+9{\%}). For an initial confidence level of 95{\%}, paired one-sided Student's t-tests with Bonferroni correction for multiple comparisons revealed a statistically significant drug effect in ventral striatum. Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti-parkinsonian properties of amantadine. Nonetheless, PET studies in parkinsonian patients using higher, clinically effective doses of amantadine may reveal more pronounced enhancements of cerebral DDC activity.",
keywords = "Caudate, Coefficient of decarboxylation, FDOPA, Fluorodopa, Parkinson's disease, PET, Putamen",
author = "Paul Deep and Alain Dagher and Abbas Sadikot and Albert Gjedde and Paul Cumming",
year = "1999",
month = "12",
day = "15",
doi = "10.1002/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1",
language = "English (US)",
volume = "34",
pages = "313--318",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

AU - Deep, Paul

AU - Dagher, Alain

AU - Sadikot, Abbas

AU - Gjedde, Albert

AU - Cumming, Paul

PY - 1999/12/15

Y1 - 1999/12/15

N2 - The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine increases the decarboxylation rate of 6-[18F]fluoro-L-DOPA (FDOPA), an exogenous substrate for DDC, in healthy human brain. Radioactivity concentrations in brain tissue of neurologically normal volunteers (n = 5) injected intravenously with FDOPA (~4.5 mCi) were recorded by positron emission tomography (PET) for 120 min, first in a baseline condition, and again following three consecutive days of treatment with amantadine (100 mg/day, p.o.). Data from four telencephalic regions of interest containing appreciable DDC activity were analyzed with the tissue slope-intercept plot, using cerebellar cortex as the reference tissue, to estimate a coefficient of in situ FDOPA decarboxylation (k3(r), min-1). Mean estimates of k3(r) were increased following amantadine treatment in caudate nucleus (+12%), putamen (+28%), ventral striatum (+27%), and frontal cortex (+9%). For an initial confidence level of 95%, paired one-sided Student's t-tests with Bonferroni correction for multiple comparisons revealed a statistically significant drug effect in ventral striatum. Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti-parkinsonian properties of amantadine. Nonetheless, PET studies in parkinsonian patients using higher, clinically effective doses of amantadine may reveal more pronounced enhancements of cerebral DDC activity.

AB - The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine increases the decarboxylation rate of 6-[18F]fluoro-L-DOPA (FDOPA), an exogenous substrate for DDC, in healthy human brain. Radioactivity concentrations in brain tissue of neurologically normal volunteers (n = 5) injected intravenously with FDOPA (~4.5 mCi) were recorded by positron emission tomography (PET) for 120 min, first in a baseline condition, and again following three consecutive days of treatment with amantadine (100 mg/day, p.o.). Data from four telencephalic regions of interest containing appreciable DDC activity were analyzed with the tissue slope-intercept plot, using cerebellar cortex as the reference tissue, to estimate a coefficient of in situ FDOPA decarboxylation (k3(r), min-1). Mean estimates of k3(r) were increased following amantadine treatment in caudate nucleus (+12%), putamen (+28%), ventral striatum (+27%), and frontal cortex (+9%). For an initial confidence level of 95%, paired one-sided Student's t-tests with Bonferroni correction for multiple comparisons revealed a statistically significant drug effect in ventral striatum. Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti-parkinsonian properties of amantadine. Nonetheless, PET studies in parkinsonian patients using higher, clinically effective doses of amantadine may reveal more pronounced enhancements of cerebral DDC activity.

KW - Caudate

KW - Coefficient of decarboxylation

KW - FDOPA

KW - Fluorodopa

KW - Parkinson's disease

KW - PET

KW - Putamen

UR - http://www.scopus.com/inward/record.url?scp=0033573286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033573286&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1

DO - 10.1002/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1

M3 - Article

VL - 34

SP - 313

EP - 318

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 4

ER -